Stock LAB B GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genomma Lab Internacional, S.A.B. de C.V.

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 06:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
18.25 MXN +2.93% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. +11.14% +28.88%
Jul. 08 Mexican Stocks Reverse Two-Session Losing Streak DJ
Jun. 27 Tranche Update on Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B)'s Equity Buyback Plan announced on March 20, 2013. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 18,932 19,061 21,614 16,849 13,161 17,249 - -
Enterprise Value (EV) 1 24,043 23,381 26,264 21,719 17,681 20,634 19,968 19,418
P/E ratio 19.3 x 12.9 x 14.9 x 12 x 13.1 x 9.24 x 8.1 x 6.55 x
Yield - - 1.78% 2.25% 1.38% 0.85% 1.83% -
Capitalization / Revenue 1.48 x 1.37 x 1.4 x 1 x 0.8 x 0.98 x 0.91 x 0.84 x
EV / Revenue 1.88 x 1.69 x 1.7 x 1.29 x 1.07 x 1.17 x 1.05 x 0.95 x
EV / EBITDA 9.35 x 7.97 x 8.18 x 6.26 x 5.12 x 5.31 x 4.69 x 4.11 x
EV / FCF 145 x 18 x 32.1 x 13.4 x 8.81 x 12.4 x 10.8 x 9.34 x
FCF Yield 0.69% 5.55% 3.11% 7.49% 11.4% 8.08% 9.3% 10.7%
Price to Book 2.38 x 2.05 x 1.96 x 1.75 x 1.44 x 1.48 x 1.28 x -
Nbr of stocks (in thousands) 1,011,839 1,011,744 1,006,240 994,639 929,461 945,144 - -
Reference price 2 18.71 18.84 21.48 16.94 14.16 18.25 18.25 18.25
Announcement Date 2/26/20 2/24/21 2/23/22 2/22/23 2/21/24 - - -
1MXN in Million2MXN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 12,756 13,867 15,460 16,859 16,467 17,684 19,006 20,453
EBITDA 1 2,571 2,932 3,210 3,471 3,454 3,885 4,257 4,728
EBIT 1 2,435 2,777 3,063 3,263 3,224 3,587 3,985 4,462
Operating Margin 19.09% 20.03% 19.81% 19.35% 19.58% 20.29% 20.97% 21.82%
Earnings before Tax (EBT) 1 1,536 2,247 2,313 2,261 1,685 2,802 3,429 4,340
Net income 1 986.7 1,478 1,451 1,397 1,031 1,984 2,270 2,702
Net margin 7.74% 10.66% 9.39% 8.29% 6.26% 11.22% 11.95% 13.21%
EPS 2 0.9700 1.460 1.440 1.410 1.080 1.976 2.252 2.785
Free Cash Flow 1 165.3 1,297 817.3 1,626 2,008 1,667 1,856 2,078
FCF margin 1.3% 9.35% 5.29% 9.65% 12.19% 9.43% 9.77% 10.16%
FCF Conversion (EBITDA) 6.43% 44.23% 25.46% 46.86% 58.13% 42.91% 43.61% 43.95%
FCF Conversion (Net income) 16.75% 87.76% 56.33% 116.43% 194.81% 84.03% 81.77% 76.92%
Dividend per Share 2 - - 0.3817 0.3817 0.1961 0.1554 0.3348 -
Announcement Date 2/26/20 2/24/21 2/23/22 2/22/23 2/21/24 - - -
1MXN in Million2MXN
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,063 4,015 4,324 4,349 4,171 4,178 4,370 4,393 3,525 4,197 4,627 4,658 3,948 4,637 4,900
EBITDA 1 889.9 826.6 892 912.4 839.9 867.3 920.1 933.7 732.3 935.6 992.3 1,010 844.6 996.4 1,059
EBIT 1 850.7 775.2 839.8 859.4 788.4 868.8 871.1 885.8 663.5 857.2 937.4 951.7 781.5 931 1,003
Operating Margin 20.94% 19.31% 19.42% 19.76% 18.9% 20.79% 19.93% 20.16% 18.82% 20.42% 20.26% 20.43% 19.79% 20.08% 20.48%
Earnings before Tax (EBT) 1 604.5 498.8 613.6 614.2 534.8 491.3 574.9 548.3 70.58 517 745.8 769.7 599.5 760.6 818.7
Net income 1 359.2 339.2 404.7 399.3 253.6 358 417.4 370.7 -115.5 372.1 492.2 508 395.7 502 540.3
Net margin 8.84% 8.45% 9.36% 9.18% 6.08% 8.57% 9.55% 8.44% -3.28% 8.87% 10.64% 10.91% 10.02% 10.83% 11.03%
EPS 2 0.3600 0.3400 0.4000 0.4000 0.2600 0.3700 0.4300 0.3900 -0.1200 0.3600 0.4697 0.4848 0.3776 0.4790 0.5156
Dividend per Share 2 0.3817 - 0.3817 - - - 0.1961 0.1961 - - - - - - -
Announcement Date 2/23/22 4/27/22 7/27/22 10/26/22 2/22/23 4/26/23 7/26/23 10/25/23 2/21/24 4/24/24 - - - - -
1MXN in Million2MXN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 5,112 4,320 4,650 4,870 4,520 3,385 2,719 2,170
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.988 x 1.473 x 1.449 x 1.403 x 1.309 x 0.8715 x 0.6387 x 0.4589 x
Free Cash Flow 1 165 1,297 817 1,626 2,008 1,667 1,857 2,078
ROE (net income / shareholders' equity) 12.6% 16.8% 14.1% 13.8% 10.6% 16.5% 16.6% 17.3%
ROA (Net income/ Total Assets) 5.28% 7.17% 6.51% 6.45% 4.88% 8.06% 9.15% -
Assets 1 18,705 20,615 22,300 21,649 21,135 24,614 24,802 -
Book Value Per Share 2 7.870 9.200 11.00 9.700 9.830 12.40 14.30 -
Cash Flow per Share 0.9900 2.000 1.440 2.050 2.360 - - -
Capex 1 839 726 630 402 247 173 393 422
Capex / Sales 6.58% 5.23% 4.08% 2.38% 1.5% 0.98% 2.07% 2.06%
Announcement Date 2/26/20 2/24/21 2/23/22 2/22/23 2/21/24 - - -
1MXN in Million2MXN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genomma Lab Internacional, S.A.B. de C.V.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
18.25 MXN
Average target price
19.67 MXN
Spread / Average Target
+7.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. Stock Genomma Lab Internacional, S.A.B. de C.V.
+28.88% 960M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+59.97% 840B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.38% 621B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.18% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.61% 319B
ABBVIE INC. Stock AbbVie Inc.
+8.44% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.68% 237B
NOVARTIS AG Stock Novartis AG
+14.40% 221B
ROCHE HOLDING AG Stock Roche Holding AG
+0.04% 220B
AMGEN INC. Stock Amgen Inc.
+9.68% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAB B Stock
  4. Financials Genomma Lab Internacional, S.A.B. de C.V.